Radio-223 (Xofigo®) for the treatment of patients with metastatic cancer
Oubiña M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L
Record ID 32016001128
Spanish
Authors' recommendations:
The evidence found is scarce and of high quality. Only one study was found on the effectiveness and safety of radium-223 versus placebo for the treatment of castration-resistant prostate cancer with bone metastases and no visceral metastases, which progressed or cannot receive treatment with docetaxel. This study was associated to a longer overall survival of approximately three months and a longer period to the first symptomatic skeletal event. No studies comparing it with other treatments with abiraterone, cabazitaxel or enzalutamide have been found.
The health technology assessments consulted and the clinical practice guidelines from the main cancer societies consider it as an alternative both for first and second line in the mentioned population. Also, the health sponsors consulted provide coverage for these patients. No recommendations or coverage policies for radio-223 were found for other types of cancer.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Neoplasms
- Neoplasms, Second Primary
- Radioisotopes
- Radium
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.